Imagine this for a moment. You haven’t been able to use your hands for six long years. A car accident left you paralyzed from the neck down. Then one day, sitting in your own courtyard, you pick up a pen. Slowly, deliberately, you write your name.
That’s not a scene from a movie. It’s the real story of Dong Hui, a 39-year-old man in China who, last October, did just that. After writing his name, he wrote "Thank you," and then the date. It was a moment made possible by a small, coin-sized implant in his brain.
This story is about more than just one man’s incredible journey. The device Dong uses, called NEO, just became the world's first invasive brain-computer interface (BCI) to be approved for commercial use. It’s out of the lab and officially available to patients. This is a huge deal, and it happened in a way that might surprise you.
So, What Is This Brain Implant, Exactly?
Let's talk about the tech. The NEO implant was developed by a Shanghai-based startup, Neuracle Technology, in partnership with researchers at the prestigious Tsinghua University.
Now, when you hear "invasive brain chip," you might picture something straight out of a sci-fi thriller, with tiny needles burrowing deep into the brain. That’s the kind of tech we often see in the headlines. But NEO is different, and that difference is the key to this whole story.
During a surgery that takes about 90 minutes, the device’s sensors are placed on the dura mater. Think of the dura mater as a tough, protective helmet that naturally covers your brain. The sensors sit right on top of this layer; they don't actually penetrate the brain tissue itself. The signals they pick up are then sent to a small transmitter on the skull, which beams the information to a computer.
For Dong, this meant his brain signals could be translated into commands for a soft, robotic glove he wears during daily training. A little over a week after his surgery, something incredible happened.
“On the ninth day of my training, my right hand successfully grabbed a ball without the glove,” he said. “That was a miraculous moment.”
Today, he continues his training at home, hoping to regain the ability to dress and feed himself, giving his aging parents a well-deserved rest. And now, thanks to this approval, thousands of others in China with similar spinal cord injuries have a new reason to hope.
How Did NEO Get Approved Before Everyone Else?
This is the question on everyone’s mind, right? We’ve been hearing about Elon Musk’s Neuralink for years, along with a handful of other high-profile BCI companies in the West. So how did this relatively quiet contender cross the finish line first?
It really comes down to two main things:
-
A “Less Invasive” Approach: Remember how NEO sits on top of the brain's protective layer? That’s a game-changer for regulators. Because it doesn't poke into the brain cortex, the risk of things like bleeding, scarring, or the signal degrading over time is significantly lower. It's a safer, less aggressive path, which makes getting a green light from medical authorities a whole lot easier.
-
China’s All-In Support: The Chinese government is throwing its full weight behind BCI technology. NEO was put on an expedited regulatory pathway, a sort of "fast track" for promising new tech. Compare that to the process in the U.S., where the FDA approval cycle can take several years of meticulous back-and-forth.
This isn’t just a one-off thing. Days after NEO was approved, China assigned it a unique code to integrate it into the national health insurance system. That’s a bureaucratic step, but it speaks volumes. It’s the first move toward making this technology accessible and affordable for ordinary patients.
Is This a "Brain-Chip Race" Between the US and China?
It’s tempting to frame this as another tech battle, a "space race" for the human brain. But when you talk to the neuroscientists and researchers in the field, they’ll tell you it’s a bit more complicated than that.
A race implies everyone is running toward the same finish line. But right now, it seems the U.S. and China have fundamentally different ideas of what "winning" looks like.
Meicen Sun, an information scientist who studies tech policy, put it perfectly. She says the U.S. is often focused on being the first to achieve state-of-the-art performance—the most powerful, the most precise. It’s about being exceptional.
China, on the other hand, seems to define winning as capturing more consumers and using technology to deliver solutions on a massive, societal scale. It’s about being accessible. These are two completely different goals.
And here’s something that might really surprise you: despite all the geopolitical tension, neurotechnology has become a rare field where U.S. and Chinese collaboration is still happening. For instance, a U.S. company called Axoft is openly working with a Chinese company and a hospital in Shanghai to test its BCI on patients in China.
What Happens Next?
The approval of NEO is like the starting gun for China’s BCI industry. The government has officially listed BCI as one of six key industries vital to the country’s future, right alongside quantum technology and humanoid robots. You can bet we’re going to see investment and development speed up dramatically over the next few years.
In fact, more devices are already in the pipeline for domestic approval. One called Beinao-1, designed to help people with movement and speech difficulties, could get the green light in just a few years.
For people like Dong Hui, this isn't about a tech race or national pride. It's about something much more fundamental. "It will be able to help not only me, but also thousands and thousands of other patients," he said. "It will bring them hope and change their lives."
And really, when you strip away all the hype and the headlines, isn't that what this technology is supposed to be all about?
